md-medicaldata

Authors

 

Željka Vrekić¹, Aleksandra Lovrenski^2,3, Dragana Tegeltija^2,3, Slađana Novković Ostojić³, Bosiljka Krajnović⁴, Anika Považan<sup>2,3

1</sup>Center for Pathology and Histology, Clinical Center of Vojvodina, Novi Sad, Serbia
²Faculty of Medicine Novi Sad, University of Novi Sad, Serbia
³Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia
⁴General Hospital of Kikinda, Serbia

 

UDK: 616.24-002.828-07

The paper was received / Rad primljen: 20.06.2019.

Accepted / Rad prihvaćen: 27.06.2019

 

Autor za korespondenciju:

Željka Vrekić, MD
Center for Pathology and Histology, Clinical Center of Vojvodina, Novi Sad, Serbia
Hajduk Veljkova 3, 21000 Novi Sad, Serbia
Mobile phone: +381 64 394 3768
e-mail: zeljkavrekic@hotmail.com

 

 

Abstract

 

Introduction: Aspergillus species can cause a wide range of lung diseases, depending on the current state of immunity and the existing pulmonary diseases. The most common manifestations of lung diseases are aspergilloma, allergic bronchopulmonary aspergillosis, invasive pulmonary aspergillosis and chronic necrotizing pulmonary aspergillosis.  Material and Methods: This prospective study included 26 patients with proven Aspergillus species infection during the period from January 2015. until December 2016.
Results: Aspergilloma was diagnosed at 23 (88.5%) patients. At 2 (7.7%) patients chronic necrotizing aspergillosis was determined, and at 1 (3.8%) patient invasive aspergillosis was diagnosed. By pathohistological analysis, the presence of Aspergillus was detected at 16 (61.5%) patients, and at 10 (38.5%) patients by microbiological diagnosis. At two patients (7.7%) Aspergillus was confirmed both pathohistologically and microbiologically. Conclusion: Since the diagnosis of diseases caused by Aspergillus species is demanding, with characteristic clinical and radiological findings, a laboratory confirmation of the fungus is essential for the final diagnosis.

 

 

Key words:

Lung disease, laboratory diagnosis, aspergillosis, pathohistological finding, microbiological analysis

 

 

 

Sažetak

 

Uvod: Aspergillus species može da izazove čitav spektar plućnih bolesti u zavisnosti od stanja imuniteta i postojećih plućnih oboljenja. Najčešće manifestacije plućnih bolesti su: aspergilom, alergijska bronhopulmonalna aspergiloza, invazivna plućna aspergiloza i hronična nekrotizirajuća plućna aspergiloza. Materijal i metode: Ova prospektivna studija obuhvatila je 26 pacijenata sa dokazanom infekcijom Aspergillus species u periodu od januara 2015. do decembra 2016. godine. Rezultati: Aspergilom je dijagnostikovan kod 23 (88,5%) pacijenata. Kod 2 (7,7%) pacijenta utvrđena je hronična nekrotizirajuća, a kod 1 (3,8%) invazivna aspergiloza. Patohistološkom analizom, prisustvo aspergilusa dokazano je kod 16 (61,5%) pacijenata, a mikrobiološkom kod 10 (38,5%) pacijenata. Kod dva (7,7%) pacijenta aspergilus je dokazan i patohistološki i mikrobiološki. Zaključak: S obzirom da je dijagnostika oboljenja izazvanih Aspergillus species zahtevna, uz karakterističan klinički i radiološki nalaz, neophodna je laboratorijska potvrda uzročnika za konačno postavljanje dijagnoze.

 

 

Ključne reči:

plućna bolest, laboratorijska dijagnoza, aspergiloza, patohistološki nalaz, mikrobiološka analiza

 

 

References:

 

1. Al-Alawi A, Ryan CF, Flint DJ, Muller LN. Aspergillus-related lung disease. Can Respir J.  2005; 12(7):377-84.
2. Zmeili OS, Soubani AO. Pulmonary aspergillosis: a clinical update. Q J Med. 2007; 100:317-34.
3. Soubani AO, Chandrasekar PH. The Clinical Spectrum of Pulmonary Aspergillosis. Chest. 2002; 121:1988-99.
4. Lovrenski A, Panjković M, Eri Ž, Klem I, Považan Đ, Ilinčić D, Milić M. Chronic necrotizing pulmonary aspergillosis. Vojnosanitetski pregled, 2011; 68(11):988-91.
5. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect. 2001;7 Suppl 2:25–31.
6. Parra I, Remacha A, Rezusta A, et al. Chronic necrotizing pulmonary aspergillosis. Med Mycol. 2004; 42:369–71.
7. Ratkov E, et al. Nalaz laboratorijskih biomarkera kod hematoloških i pulmoloških bolesnika s visokim rizikom za aspergilozu. Srp Arh Celok Lek. 2012; 140(5-6):290-8.
8. Kaiser LR. Fishman's Pulmonary Diseases and Disorders. 4th ed. McGraw-Hill. 2008. p. 1853-4. 
9. Latge J. Aspergillus fumigatus and aspergillosis. Clin Micro Rev. 1999; 12:310-50.
10. Karakašević B. Aspergillus. In: Priručnik standradnih metoda za mikrobiološki rutinski rad. 3rd ed. Beograd: Medicinska knjiga; 1967. p. 1095-7.
11. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009; 3(22):447–65.
12. De Pauw B, Walsh T, Donnelly P, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/Invasive fungal infections cooperative group and the National institute of allergy and Infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008; 46:1813-21.
13. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis. Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125:375-8.
14. Kappe1 R, Rimek D. Mykoserologie – sind wir weitergekommen? Aspergillus; Mycoserology – did we move on? Aspergillus. Blackwell Publishing Ltd Mycoses. 2010; 53 (1):26–9.
15. Chang KP, Sanghoon J. Results of surgical tretmant for pulmonary aspergilloma. Europen Journal of Cardio-thoracic Surgery. 2002; 21:918-23.
16. Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clinical Microbiology Rev. 2008; 
17. 21(2):305-33.
18. Eri Ž. Tuberculosis. In: Pathology of respiratory system. Patologija respiratornog sistema.  2nd  ed. Novi Sad: Symbol; 2003. p. 78-88.

PDF Vrekić Ž. et al. • MD-Medical Data 2019;11(2): 093-097